Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy
Abstract In one decade, immunotherapy based on immune checkpoint blockades (ICBs) has become a new pillar of cancer treatment following surgery, radiation, chemotherapy, and targeted therapies. However, not all cancer patients benefit from single or combination therapy with anti-CTLA-4 and anti-PD-1...
Guardat en:
| Autors principals: | , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
BMC
2023-09-01
|
| Col·lecció: | Journal of Hematology & Oncology |
| Matèries: | |
| Accés en línia: | https://doi.org/10.1186/s13045-023-01499-1 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|